Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1865-1877

  Chang, Hui Hua ^a,b   Song, Zuohe ^a,b   Wisner, Lee ^a   Tripp, Tina ^b   Gokhale, Vijay ^b   Meuillet, Emmanuelle J ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

Author keywords

Anti tumor; Cancer; Drug design; Inflammation; Prostaglandin E2

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1; PGE 0001; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG TUMOR; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACODYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RECTUM TUMOR; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DINOPROSTONE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; MICE; MICE, SCID; MICROSOMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS E; SURFACE PLASMON RESONANCE;

EID: 84867768428     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9748-8     Document Type: Article

References (51)

1. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294(5548):1871-1875. doi: 10.1126/science.294.5548.1871
2. Legler DF, Bruckner M, Uetz-von Allmen E, Krause P (2010) Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 42(2):198-201. doi: 10.1016/j.biocel.2009.09. 015
3. Bingham CO 3rd, Austen KF (1999) Phospholipase A2 enzymes in eicosanoid generation. Proc Assoc Am Physicians 111(6):516-524
4. Pugh S, Thomas GA (1994) Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35(5):675-678
5. Williams CS, Smalley W, DuBois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100(6):1325-1329. doi: 10.1172/JCI119651
6. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN (1998) Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19(12):2195-2199
7. Rahme E, Barkun AN, Toubouti Y, Bardou M (2003) The cyclooxygenase-2- selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125(2):404-412. doi: S0016508503008801
8. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102. doi: 10.1056/NEJMoa050493
9. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080. doi: 10.1056/NEJMoa050405
10. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59(3):207-224. doi: 10.1124/pr.59.3.1
11. Friesen RW, Mancini JA (2008) Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J Med Chem 51(14):4059-4067. doi: 10.1021/jm800197b
12. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96(13):7220-7225
13. Watanabe K, Kurihara K, Suzuki T (1999) Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart. Biochim Biophys Acta 1439(3):406-414
14. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275(42):32775-32782. doi: 10.1074/jbc.M003504200
15. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (2002) Characterization of microsomal, glutathione dependent prostaglandin E synthase. Adv Exp Med Biol 507:287-291
16. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7(9):2669-2674
17. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, Dannenberg AJ (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7(12):3971-3976
18. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278(21):19396-19405. doi: 10.1074/jbc.M213290200
19. van Rees BP, Sivula A, Thoren S, Yokozaki H, Jakobsson PJ, Offerhaus GJ, Ristimaki A (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 107(4):551-556. doi: 10.1002/ijc.11422
20. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S (2006) Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 208(3):356-363. doi: 10.1002/path.1907
21. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5:62. doi: 10.1186/1476-4598-5-62
22. Hasan S, Satake M, Dawson DW, Funahashi H, Angst E, Go VL, Reber HA, Hines OJ, Eibl G (2008) Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 37(2):121-127. doi: 10.1097/MPA.0b013e31816618ba
23. Hanaka H, Pawelzik SC, Johnsen JI, Rakonjac M, Terawaki K, Rasmuson A, Sveinbjornsson B, Schumacher MC, Hamberg M, Samuelsson B, Jakobsson PJ, Kogner P, Radmark O (2009) Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA 106(44):18757-18762. doi: 10.1073/pnas.0910218106
24. Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y, Ishii T, Uematsu S, Akira S, Hara S, Kudo I (2010) Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J 425(2):361-371. doi: 10.1042/BJ20090045
25. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68(9):3251-3259. doi: 10.1158/0008-5472.CAN-07-6100
26. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372(9651):1756-1764. doi: 10.1016/S0140-6736(08)61490-7
27. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116(5):1391-1399
28. Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW (2010) mPGES-1 as a target for cancer suppression: a comprehensive invited review Phospholipase A2 and lipid mediators. Biochimie 92(6):660-664. doi: 10.1016/j.biochi.2010.02.006
29. Swingle KF, Moore GG, Grant TJ (1976) 4-nitro-2- phenoxymethanesulfonanilide (R-805): a chemically novel anti-inflammatory agent. Arch Int Pharmacodyn Ther 221(1):132-139
30. Thoren S, Jakobsson PJ (2000) Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur J Biochem 267(21):6428-6434
31. Arai I, Hamasaka Y, Futaki N, Takahashi S, Yoshikawa K, Higuchi S, Otomo S (1993) Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commun Chem Pathol Pharmacol 81(3):259-270
32. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, Otomo S (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24(1):105-110
33. Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Methot N, Rubin J, Friesen RW (2005) Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 15(14):3352-3355
34. Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S, Albrecht W, Werz O (2008) Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326(3):975-982
35. Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O (2008) Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Med Chem 51(24):8068-8076
36. Koeberle A, Bauer J, Verhoff M, Hoffmann M, Northoff H, Werz O (2009) Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res Commun 388(2):350-354
37. Koeberle A, Pollastro F, Northoff H, Werz O (2009) Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br J Pharmacol 156(6):952-961
38. Thoren S, Weinander R, Saha S, Jegerschold C, Pettersson PL, Samuelsson B, Hebert H, Hamberg M, Morgenstern R, Jakobsson PJ (2003) Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 278(25):22199-22209. doi: 10.1074/jbc.M303227200
39. Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ (2008) Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 7(9):2621-2632. doi: 10.1158/1535-7163.MCT-07-2276
40. Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL (2010) Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol 79(10):1445-1454. doi: 10.1016/j.bcp.2010. 01.003
41. Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM (1997) Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 40(3):209-214
42. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G (2010) Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 9(3):706-717. doi: 10.1158/1535-7163.MCT-09- 0985
43. Terzuoli E, Donnini S, Giachetti A, Iniguez MA, Fresno M, Melillo G, Ziche M (2010) Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin Cancer Res 16(16):4207-4216. doi: 10.1158/1078-0432.CCR-10-0156
44. Lim SC, Cho H, Lee TB, Choi CH, Min YD, Kim SS, Kim KJ (2010) Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med J 51(5):692-699. doi: 10.3349/ymj.2010.51.5.692
45. Elander N, Ungerback J, Olsson H, Uematsu S, Akira S, Soderkvist P (2008) Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 372(1):249-253. doi: 10.1016/j.bbrc.2008.05.026
46. Cote B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Masse F, Methot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW (2007) Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 17(24):6816-6820. doi: 10.1016/j.bmcl.2007.10.033
47. Xu D, Rowland SE, Clark P, Giroux A, Cote B, Guiral S, Salem M, Ducharme Y, Friesen RW, Methot N, Mancini J, Audoly L, Riendeau D (2008) MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 326(3):754-763. doi: 10.1124/jpet.108.138776
48. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63(18):5962-5969
49. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA (2003) The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 17(11):1411-1421. doi: 10.1096/fj.02-1038com
50. Ohama T, Okada M, Murata T, Brautigan DL, Hori M, Ozaki H (2008) Sphingosine-1-phosphate enhances IL-1{beta}-induced COX-2 expression in mouse intestinal subepithelial myofibroblasts. Am J Physiol Gastrointest Liver Physiol 295(4):G766-775. doi: 10.1152/ajpgi.90423.2008
51. Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, Obeid LM (2009) A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J 23(1):143-152. doi: 10.1096/fj.08-118109